Dr James expressed a willingness to collaborate with the Working Party on providing samples from their earlier study while noting he and his colleagues wished to avoid defrosting and refreezing their stored sera on too many occasions. Read more about Dr James expressed a willingness to collaborate with the Working Party on providing samples from their earlier study while noting he and his colleagues wished to avoid defrosting and refreezing their stored sera on too many occasions.
Dr Brian McClelland contacted Dr James regarding an abstract of prospective study on possible non-A non-B post-transfusion and the availability of samples from their study. Read more about Dr Brian McClelland contacted Dr James regarding an abstract of prospective study on possible non-A non-B post-transfusion and the availability of samples from their study.
Dr Brian McClelland outlined two options for the 1974 UK prospective hepatitis study and suggested that a multi-centre study of this type would cost between £250,000 and £500,000. Read more about Dr Brian McClelland outlined two options for the 1974 UK prospective hepatitis study and suggested that a multi-centre study of this type would cost between £250,000 and £500,000.
The MRC sought further information on Dr Gunson's request on samples from the 1974 UK prospective study on transfusion associated hepatitis, including where Dr Gunson believed the samples might be held. Read more about The MRC sought further information on Dr Gunson's request on samples from the 1974 UK prospective study on transfusion associated hepatitis, including where Dr Gunson believed the samples might be held.
Dr Gunson asked the MRC if samples from the 1974 UK prospective study on transfusion associated hepatitis could be made available. Read more about Dr Gunson asked the MRC if samples from the 1974 UK prospective study on transfusion associated hepatitis could be made available.
At its first meeting, the UK Working Party on Transfusion-Associated Hepatitis agreed that Dr Gunson would ask the MRC if samples from the 1974 UK prospective study on transfusion associated hepatitis could be made available. Read more about At its first meeting, the UK Working Party on Transfusion-Associated Hepatitis agreed that Dr Gunson would ask the MRC if samples from the 1974 UK prospective study on transfusion associated hepatitis could be made available.
At its first meeting, the UK Working Party on Transfusion-Associated Hepatitis agreed that Dr Brian McClelland would produce an outline study protocol, which might include non-specific markers like ALT level and/or the presence of anti-HBc in donors. Read more about At its first meeting, the UK Working Party on Transfusion-Associated Hepatitis agreed that Dr Brian McClelland would produce an outline study protocol, which might include non-specific markers like ALT level and/or the presence of anti-HBc in donors.
The merits and drawbacks of NANBH surrogate screening were discussed in an editorial in The Lancet. Read more about The merits and drawbacks of NANBH surrogate screening were discussed in an editorial in The Lancet.
The DHSS Advisory Group on Hepatitis endorsed the Third Report of the Advisory Group on Testing for the Presence of Hepatitis B Surface Antigen and Its Antibody, advising against NANBH screening. Read more about The DHSS Advisory Group on Hepatitis endorsed the Third Report of the Advisory Group on Testing for the Presence of Hepatitis B Surface Antigen and Its Antibody, advising against NANBH screening.
The Advisory Group on Testing for the Presence of Hepatitis B Surface Antigen and Its Antibody advised against screening tests for NANBH in screening blood donors. Read more about The Advisory Group on Testing for the Presence of Hepatitis B Surface Antigen and Its Antibody advised against screening tests for NANBH in screening blood donors.